Colon-Release Cholestyramine Pellets for Bile Acid Malabsorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bile acid malabsorption, particularly those using cholestyramine, are associated with significant side effects such as constipation, interactions with other medications, and malabsorption of fats and fat-soluble vitamins, and lack targeted delivery to the colon, leading to suboptimal patient compliance and efficacy.
Innovation Solution
Development of an oral formulation comprising small, stable cholestyramine pellets coated with a colon-release coating that ensures more than 70% of cholestyramine is released in the colon, minimizing release in the small intestine and reducing interactions with other drugs and nutrients, thereby improving tolerance and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cholestyramine is administered orally to treat bile acid malabsorption, then excess bile acids are bound in the gastrointestinal tract, but significant side effects occur including constipation, drug interactions, and malabsorption of fats and fat-soluble vitamins
Solution Approach 1:
The patent applies local quality by creating a colon-release formulation where cholestyramine is delivered specifically to the colon rather than being released throughout the entire gastrointestinal tract. This localized delivery ensures bile acid binding occurs where needed (in the colon where bile acids accumulate) while avoiding harmful interactions in the small intestine, thereby maintaining treatment efficacy while reducing side effects.
Solution Approach 2:
The patent uses a colon-release coating as an intermediary mechanism that controls where and when cholestyramine becomes active. This coating acts as a mediator that prevents premature release in the stomach and small intestine, allowing the active ingredient to reach its target site (colon) intact, thus reducing unwanted interactions while maintaining therapeutic effect.
2Reliability
If cholestyramine is released in the small intestine, then it can bind bile acids, but it interacts with other medications and nutrients causing reduced absorption
Solution Approach 1:
The patent extracts the harmful interaction component by preventing cholestyramine from being present in the small intestine where drug interactions occur. The colon-release formulation extracts the active ingredient from the small intestine environment and delivers it directly to the colon, thereby separating the therapeutic function (bile acid binding) from the harmful interactions with other medications and nutrients.
Solution Approach 2:
The colon-release coating serves as an intermediary that prevents direct contact between cholestyramine and other substances in the small intestine. This mediator allows the formulation to maintain its bile acid binding capability while avoiding harmful interactions by controlling the spatial and temporal release of the active ingredient.
3Reliability
If conventional cholestyramine formulations are used, then bile acids are bound throughout the gastrointestinal tract, but patient compliance is poor due to side effects and complex dosing
Solution Approach 1:
The patent improves patient compliance by applying local quality through colon-specific delivery. This targeted approach maintains treatment efficacy while reducing the burden of therapy - patients experience fewer side effects and can use simpler dosing regimens (once or twice daily) compared to conventional formulations that require multiple daily doses and have poor tolerability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively binds excess bile acids in the colon, reducing colonic secretion and motility, while minimizing side effects and drug interactions, thus providing a more tolerable and effective treatment for bile acid malabsorption.
Implementation Method 1
a colon release coating around said pellets, wherein more than 70% of the cholestyramine is released in the colon
Implementation Method 2
coated with a colon release coating that ensures more than 70% of cholestyramine is released in the colon
Implementation Method 3
Cholestyramine (or colestyramine; CAS Number 11041-12-6) is a strongly basic anion-exchange resin that is practically insoluble in water and is not absorbed from the gastrointestinal tract. Instead, it absorbs and combines with the bile acids in the intestine to form an insoluble complex
Implementation Method 4
a colon release coating around said pellets, wherein more than 70% of the cholestyramine is released in the colon
Data Source
Figure 1A~1C
Figure 2
Figure 3
AI summary
The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.